2026-01-22 - Analysis Report
**Company Overview:**
Regeneron Pharmaceuticals, Inc. is a biotechnology company that researches and develops treatments for serious diseases.

**Return Rate Comparison:**
- Ticker to review: REGN
- Cumulative return of review stock: 28.13%
- Cumulative return of comparison stock (S&P 500, VOO): 91.55%
- Divergence (max: 31.70, min: -93.00, current: -67.90, relative divergence: 20.10%)

The review stock's cumulative return is significantly lower than the comparison stock (S&P 500, VOO), with a divergence of -67.90.

**Alpha, Beta Analysis:**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -14.0% | 22.4% | -19.0% | 1.2 | 39.6B |
| 2017-2019  | -3.0% | 28.6% | -21.0% | 1.0 | 39.8B |
| 2018-2020  | 2.0% | 28.6% | -19.0% | 0.7 | 51.2B |
| 2019-2021  | 29.0% | 28.6% | -15.0% | 0.6 | 66.9B |
| 2020-2022  | 55.0% | 14.4% | 56.0% | 0.6 | 76.5B |
| 2021-2023  | 46.0% | 14.4% | 45.0% | 0.6 | 93.1B |
| 2022-2024  | -7.0% | 30.9% | -26.0% | 0.6 | 75.5B |
| 2023-2025  | -4.0% | 45.4% | -66.0% | 0.6 | 81.8B |

The CAGR (compound annual growth rate) shows fluctuations in different periods, ranging from -14.0% to 55.0%. The Alpha and Beta analysis indicate varying performance levels and market sensitivity.

**Recent Stock Price Fluctuations:**
- Close: $749.33
- Last-market: $749.33 (previous close was $733.78, change was 2.12%)
- 5-day SMA: $742.44
- 20-day SMA: $771.23, 60-day SMA: $726.51

The stock's price has rebounded slightly, with its 5-day moving average below the current value. The 20-day moving average is above the current price, indicating potential resistance.

**RSI, PPO, and Delta_Previous_Relative_Divergence:**
- Market Risk Indicator (MRI): 0.80
- RSI: 42.50
- PPO: -1.02
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium (MRI 0.80)
- Recent (20 days) relative divergence change: -8.10 (worsening)
- 7-day Rank change: 33 (rank up)
- 7-day Dynamic Expected Return change: -3.30 (worsening)
- If a large fluctuation issue occurred, reflect the sharp rebound or decline in the Expected Return.

The RSI and PPO indicators suggest mixed signals, with possible caution advised due to the lower value of the RSI (42.50) and the negative value of PPO (-1.02). The MRI is classified as medium risk, and the relative divergence worsened in the past 20 days.

**Expected Return:**
- Expected Return: -48.00%
- Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

The negative Expected Return value indicates potential concerns regarding this stock's future performance.

**Recent News & Significant Events:**
- [2026-01-21] 40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan (news.google.com)
- [2026-01-21] YieldBoost REGN From 0.5% To 5.6% Using Options - Nasdaq (news.google.com)
- [2026-01-06] REGN vs. ILMN: Which Stock Should Value Investors Buy Now? - Yahoo Finance (news.google.com)
- [2026-01-18] Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC - MarketBeat (news.google.com)
- [2026-01-02] Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative (news.google.com)
- [2026-01-18] Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st (news.google.com)

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 825.23 / 1057.00 / 630.00

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

The quarterly EPS (Earnings Per Share) has shown slight variations, ranging from 7.58 to 14.09. Revenue has mostly ranged from 3.03B$ to 3.75B$.

**Financial Information:**
**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

**Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

The revenue has fluctuated between 3.03B$ and 3.79B$, while profit margins have generally been above 84%. Equity has increased in most quarters, with ROE (Return on Equity) generally ranging from 2.75% to 4.72%.

**Comprehensive Analysis:**
Based on the provided data, the comprehensive analysis combines the results from the previous sections. Key takeaways include:
- Low cumulative return and high relative divergence indicate that the review stock's performance is lagging compared to the comparison stock (S&P 500, VOO).
- The Alpha and Beta analysis indicate varying performance levels and market sensitivity.
- Recent stock price fluctuations show a slight rebound, with the 5-day moving average below the current value and the 20-day moving average above it.
- RSI and PPO indicators suggest mixed signals, with possible caution advised due to the lower RSI value and the negative PPO value. The MRI is classified as medium risk, with relative divergence worsening in the past 20 days.
- The negative Expected Return indicates potential concerns regarding the stock's future performance.
- Recent news highlights positive developments, but overall market risk is considered medium.
- Analyst opinions are generally optimistic with a Buy consensus, but target prices have a wide range (avg/high/low: 825.23 / 1057.00 / 630.00).
- Revenue has fluctuated between 3.03B$ and 3.79$, while profit margins have generally been above 84%. Equity has increased in most quarters, with ROE generally ranging from 2.75% to 4.72%.

Considering these results, investors should approach this stock with caution and carefully consider their investment decisions based on their risk tolerance and investment strategies.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.